These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38605963)

  • 41. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.
    Ho NI; Camps MGM; de Haas EFE; Ossendorp F
    Eur J Immunol; 2018 Jul; 48(7):1164-1173. PubMed ID: 29676785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation.
    Wang X; Li H; Matte-Martone C; Cui W; Li N; Tan HS; Roopenian D; Shlomchik WD
    Blood; 2011 Dec; 118(24):6426-37. PubMed ID: 21963602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aptamer-targeted antigen delivery.
    Wengerter BC; Katakowski JA; Rosenberg JM; Park CG; Almo SC; Palliser D; Levy M
    Mol Ther; 2014 Jul; 22(7):1375-1387. PubMed ID: 24682172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expressed Salmonella antigens within macrophages enhance the proliferation of CD4+ and CD8+ T lymphocytes by means of bystander dendritic cells.
    Eguchi M; Sekiya Y; Kikuchi Y; Takaya A; Yamamoto T; Matsui H
    FEMS Immunol Med Microbiol; 2007 Aug; 50(3):411-20. PubMed ID: 17573927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
    Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
    J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins.
    Fessenden TB; Stopfer LE; Chatterjee F; Zulueta J; Mesfin J; Cordero Dumit T; Reijers I; Hoefsmit EP; Blank C; White F; Spranger S
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35820727
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Calcineurin inhibitors block MHC-restricted antigen presentation in vivo.
    Lee YH; Lee YR; Im SA; Park SI; Kim KH; Gerelchuluun T; Song S; Kim K; Lee CK
    J Immunol; 2007 Nov; 179(9):5711-6. PubMed ID: 17947643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells.
    Moffat JM; Cheong WS; Villadangos JA; Mintern JD; Netter HJ
    Vaccine; 2013 Apr; 31(18):2310-6. PubMed ID: 23473776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
    Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
    Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of major histocompatibility complex Class I antigen presentation by hepatitis C virus core protein in myeloid dendritic cells.
    O'Beirne J; Mitchell J; Farzaneh F; Harrison PM
    Virology; 2009 Jun; 389(1-2):1-7. PubMed ID: 19409594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.
    Rosalia RA; Quakkelaar ED; Redeker A; Khan S; Camps M; Drijfhout JW; Silva AL; Jiskoot W; van Hall T; van Veelen PA; Janssen G; Franken K; Cruz LJ; Tromp A; Oostendorp J; van der Burg SH; Ossendorp F; Melief CJ
    Eur J Immunol; 2013 Oct; 43(10):2554-65. PubMed ID: 23836147
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells.
    Mitchell DA; Nair SK; Gilboa E
    Eur J Immunol; 1998 Jun; 28(6):1923-33. PubMed ID: 9645374
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells.
    Tagliani E; Guermonprez P; Sepúlveda J; López-Bravo M; Ardavín C; Amigorena S; Benvenuti F; Burrone OR
    J Immunol; 2008 Mar; 180(5):3201-9. PubMed ID: 18292544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells.
    Svensson M; Stockinger B; Wick MJ
    J Immunol; 1997 May; 158(9):4229-36. PubMed ID: 9126984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the gut vascular endothelium induces gut effector CD8 T cell responses via cross-presentation by dendritic cells.
    Bourges D; Zhan Y; Brady JL; Braley H; Caminschi I; Prato S; Villadangos JA; Lew AM
    J Immunol; 2007 Nov; 179(9):5678-85. PubMed ID: 17947639
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of mizoribine on MHC-restricted exogenous antigen presentation in dendritic cells.
    Song Y; Han S; Kim H; Kim K; Kwon J; Lee SJ; Ha NJ; Lee YH; Lee CK; Kim K
    Arch Pharm Res; 2006 Dec; 29(12):1147-53. PubMed ID: 17225465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
    McMenamin C; Holt PG
    J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1.
    Ackerman AL; Cresswell P
    J Immunol; 2003 Apr; 170(8):4178-88. PubMed ID: 12682250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.